Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY24 results · Jan–Mar 2024
Solara Active Pharma Sciences reported revenue from operations of ₹299.43 crore (down 21.3% from Q4 FY23) and net loss of ₹255.45 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 299.43 | 380.62 | −21.3% | 248.73 | +20.4% |
| Other income | 1.70 | 4.68 | −63.7% | 0.45 | +277.8% |
| Total income | 301.13 | 385.30 | −21.8% | 249.18 | +20.8% |
| Profit before tax | (166.66) | 5.04 | Turned loss | (275.34) | Loss narrowed |
| Net profit for the period | (255.45) | 3.76 | Turned loss | (275.34) | Loss narrowed |
| Attributable to shareholders of the company | (255.34) | 3.77 | Turned loss | (275.34) | Loss narrowed |
| EPS, basic (₹) | (70.93) | 1.05 | Turned loss | (76.49) | Loss narrowed |
| Net margin (%) | -85.3 | 1.0 | -110.7 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 299.43 | 380.62 | −21.3% | 248.73 | +20.4% |
| Other income | 1.63 | 5.12 | −68.2% | 0.44 | +270.5% |
| Total income | 301.06 | 385.74 | −22.0% | 249.17 | +20.8% |
| Profit before tax | (167.62) | 8.31 | Turned loss | (275.33) | Loss narrowed |
| Net profit for the period | (256.41) | 6.46 | Turned loss | (275.33) | Loss narrowed |
| EPS, basic (₹) | (71.23) | 1.79 | Turned loss | (76.49) | Loss narrowed |
| Net margin (%) | -85.6 | 1.7 | -110.7 |
Consolidated
- Filed with BSE
- 19 Jul 2024, 14:26 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Jul 2024, 14:26 IST
- Board meeting
- 29 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE